Vedolizumab 300 mg
2014-100756
Approved small_molecule completed
Quick answer
Vedolizumab 300 mg for Colitis, Ulcerative is a Approved program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Colitis, Ulcerative
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed